A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem in the Treatment of Subjects With Ventilator-Associated Pneumonia.

Trial Profile

A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem in the Treatment of Subjects With Ventilator-Associated Pneumonia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2014

At a glance

  • Drugs Doripenem (Primary) ; Imipenem/cilastatin
  • Indications Bacterial infections; Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 17 Jul 2012 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 17 Jul 2012 Actual number of patients changed from 273 to 274, as reported by ClinicalTrials.gov.
    • 23 May 2012 Primary endpoint 'Clinical-cure-rate' has not been met according to results presented at the 108th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top